Harout Semerjian
Chief Executive Officer bei GLYCOMIMETICS, INC.
Vermögen: 75 000 $ am 31.03.2024
Profil
Harout Semerjian is the President, Chief Executive Officer & Director at GlycoMimetics, Inc. He was previously the President, Chief Executive Officer & Director at Immunomedics, Inc. for a brief period in 2020.
Before that, he was the Chief Commercial Officer & Executive VP at Ipsen SA from 2018 to 2020 and the Managing Director at Ipsen Pharma SAS.
Semerjian holds an MBA from both Queen's University and Cornell University, as well as an undergraduate degree from Lebanese American University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0,04% | 15.03.2024 | 25 000 ( 0,04% ) | 75 000 $ | 31.03.2024 |
Aktive Positionen von Harout Semerjian
| Unternehmen | Position | Beginn |
|---|---|---|
| GLYCOMIMETICS, INC. | Chief Executive Officer | 06.08.2021 |
Ehemalige bekannte Positionen von Harout Semerjian
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOMEDICS, INC. | Chief Executive Officer | 27.05.2020 |
| IPSEN | Corporate Officer/Principal | 01.04.2020 |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Corporate Officer/Principal | - |
Ausbildung von Harout Semerjian
| Queen's University | Masters Business Admin |
| Cornell University | Masters Business Admin |
| Lebanese American University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IPSEN | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
